Trial Profile
A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; MK 2206 (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Biomarker
- 09 Nov 2012 New trial record